Christian J Gomez1, Alma Diaz Quinones1, Amy Melissa Gonell1, Tesil Nedumkallel Sani1, Otoniel Ysea-Hill1, Dhanya Baskaran1, Jorge G Ruiz2,3. 1. Miami VA Healthcare System Geriatric Research, Education and Clinical Center (GRECC), Veterans Successful Aging for Frail Elders (VSAFE), Bruce W. Carter Miami VAMC, GRECC (11GRC), 1201 NW 16th Street, Miami, FL, 33125, USA. 2. Miami VA Healthcare System Geriatric Research, Education and Clinical Center (GRECC), Veterans Successful Aging for Frail Elders (VSAFE), Bruce W. Carter Miami VAMC, GRECC (11GRC), 1201 NW 16th Street, Miami, FL, 33125, USA. j.ruiz@miami.edu. 3. University of Miami Miller School of Medicine, Miami, FL, USA. j.ruiz@miami.edu.
Abstract
BACKGROUND: Frailty, a clinical syndrome characterized by vulnerability to stressors resulting from multisystemic loss of physiological reserve. The use of benzodiazepines in older adults has been associated with confusion, sedation, and cognitive impairment, which in turn may lead to frailty. AIMS: The purpose of this study was to determine the cross-sectional association between frailty and chronic past or current use of benzodiazepine drugs among older US Veterans. METHODS/ DESIGN: This is a cross-sectional study of community-dwelling older Veterans who had determinations of frailty. Benzodiazepine prescription data were obtained via EHR. A 31-item VA Frailty Index (VA-FI) was generated at the time of the assessment. We categorized Veterans into robust (FI ≤ 0.10), pre-frail (FI 0.10-0.21), and Frail (FI ≥ 0.21). After adjusting for sociodemographic characteristics, we calculated ORs and 95% CIs using a binomial logistic regression (BLR) model to assess the cross-sectional association between benzodiazepine use and frailty. RESULTS: Population sample consisted of 17,423 Veterans, mean age 75.53 (SD = 8.03) years, 70.80% Caucasian, 97.34% male, 14,545 (83.50%) patients were non-users of benzodiazepine drugs, 2408 (13.80%) had a past use, and 470 (2.70%) were current users. In BLR, individuals with past (OR 2.51, 95% CI 2.30-2.74, p < .001) or current (OR 2.36, 95% CI 1.96-2.83, p < .001) use showed a higher association with frailty as compared to individuals who were non-users. CONCLUSIONS: The use of benzodiazepine was cross-sectionally associated with frailty in older Veterans. These results suggest that screening for frailty in patients with past or current exposure to benzodiazepine medications may be necessary for proper management.
BACKGROUND: Frailty, a clinical syndrome characterized by vulnerability to stressors resulting from multisystemic loss of physiological reserve. The use of benzodiazepines in older adults has been associated with confusion, sedation, and cognitive impairment, which in turn may lead to frailty. AIMS: The purpose of this study was to determine the cross-sectional association between frailty and chronic past or current use of benzodiazepine drugs among older US Veterans. METHODS/ DESIGN: This is a cross-sectional study of community-dwelling older Veterans who had determinations of frailty. Benzodiazepine prescription data were obtained via EHR. A 31-item VA Frailty Index (VA-FI) was generated at the time of the assessment. We categorized Veterans into robust (FI ≤ 0.10), pre-frail (FI 0.10-0.21), and Frail (FI ≥ 0.21). After adjusting for sociodemographic characteristics, we calculated ORs and 95% CIs using a binomial logistic regression (BLR) model to assess the cross-sectional association between benzodiazepine use and frailty. RESULTS: Population sample consisted of 17,423 Veterans, mean age 75.53 (SD = 8.03) years, 70.80% Caucasian, 97.34% male, 14,545 (83.50%) patients were non-users of benzodiazepine drugs, 2408 (13.80%) had a past use, and 470 (2.70%) were current users. In BLR, individuals with past (OR 2.51, 95% CI 2.30-2.74, p < .001) or current (OR 2.36, 95% CI 1.96-2.83, p < .001) use showed a higher association with frailty as compared to individuals who were non-users. CONCLUSIONS: The use of benzodiazepine was cross-sectionally associated with frailty in older Veterans. These results suggest that screening for frailty in patients with past or current exposure to benzodiazepine medications may be necessary for proper management.
Authors: Linda P Fried; Luigi Ferrucci; Jonathan Darer; Jeff D Williamson; Gerard Anderson Journal: J Gerontol A Biol Sci Med Sci Date: 2004-03 Impact factor: 6.053
Authors: Jeremy Walston; Karen Bandeen-Roche; Brian Buta; Howard Bergman; Thomas M Gill; John E Morley; Linda P Fried; Thomas N Robinson; Jonathan Afilalo; Anne B Newman; Carlos López-Otín; Rafa De Cabo; Olga Theou; Stephanie Studenski; Harvey J Cohen; Luigi Ferrucci Journal: J Am Geriatr Soc Date: 2019-05-02 Impact factor: 5.562
Authors: Kris M Jamsen; J Simon Bell; Sarah N Hilmer; Carl M J Kirkpatrick; Jenni Ilomäki; David Le Couteur; Fiona M Blyth; David J Handelsman; Louise Waite; Vasi Naganathan; Robert G Cumming; Danijela Gnjidic Journal: J Am Geriatr Soc Date: 2016-01 Impact factor: 5.562
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Ariela R Orkaby; Lisa Nussbaum; Yuk-Lam Ho; David Gagnon; Lien Quach; Rachel Ward; Rachel Quaden; Enzo Yaksic; Kelly Harrington; Julie M Paik; Dae H Kim; Peter W Wilson; J Michael Gaziano; Luc Djousse; Kelly Cho; Jane A Driver Journal: J Gerontol A Biol Sci Med Sci Date: 2019-07-12 Impact factor: 6.053